How Much Does Amlodipine Lower Blood Pressure?

Understand how amlodipine effectively lowers blood pressure, its typical impact, and factors influencing individual results and timing.

Amlodipine typically lowers blood pressure by roughly 10 to 15 mmHg systolic and 6 to 10 mmHg diastolic, though the exact drop depends heavily on your starting dose, your baseline blood pressure, and individual biology. In clinical trials, reductions have ranged from modest single-digit drops at the lowest dose to much steeper falls in people who started with severely elevated readings. The drug’s unusually long duration of action and dose-dependent response make it one of the most widely prescribed blood pressure medications worldwide, but the numbers on the label only tell part of the story.

The Dose Makes the Difference

Amlodipine comes in three standard strengths: 2.5 mg, 5 mg, and 10 mg, all taken once a day. The relationship between dose and blood pressure reduction is genuinely stepwise. In a dose-response study of patients with mild to moderate hypertension, target blood pressure was reached in about 41% of patients on 2.5 mg, 56% on 5 mg, and 73% on 10 mg, compared with 25% on placebo. A separate double-blind trial confirmed that 2.5 mg is the minimum effective dose, with blood pressure reductions growing progressively at higher doses over eight weeks of treatment.

Most prescribers start patients at 5 mg and move to 10 mg if needed after a few weeks. In a head-to-head comparison with atenolol (a beta-blocker), patients on an average amlodipine dose of about 8.8 mg saw their supine blood pressure fall by roughly 13/10 mmHg, while standing blood pressure dropped by about 12/10 mmHg. Those numbers are a reasonable benchmark for what a mid-to-high dose does in someone with moderate hypertension, but they are averages, and individual responses can differ substantially.

Why It Keeps Working Around the Clock

One reason amlodipine stands out among blood pressure drugs is its pharmacokinetic profile. It has a half-life of 35 to 50 hours, meaning it takes that long for your body to clear half the dose from your bloodstream. That is far longer than most competing calcium channel blockers, which is why a single daily pill can maintain blood pressure control for well over 24 hours. The practical payoff is that if you happen to miss a dose, your coverage does not evaporate overnight. Few blood pressure medications offer that kind of buffer.

This long duration also means amlodipine does not produce a sharp peak followed by a trough the way shorter-acting drugs can. In a study comparing amlodipine and losartan using 24-hour ambulatory monitoring, amlodipine delivered a higher “trough-to-peak” ratio for systolic blood pressure, meaning its effect was more even throughout the day and night. That consistency matters because uneven blood pressure control can itself be a risk factor for cardiovascular events.

How It Stacks Up Against Other Medications

For most patients, amlodipine brings blood pressure down about as well as the other first-line drug classes: ACE inhibitors, ARBs, beta-blockers, and thiazide diuretics. In a year-long trial comparing amlodipine to an ACE inhibitor in patients with kidney-related hypertension, both produced comparable blood pressure reductions, lowering readings from around 165/101 to roughly 138/81 mmHg. The amlodipine-versus-atenolol trial mentioned earlier found no statistically significant difference between the two drugs’ blood pressure effects.

There are situations where differences do emerge. In patients with obstructive sleep apnea, for example, atenolol was more effective at lowering office diastolic pressure than amlodipine, enalapril, hydrochlorothiazide, or losartan, though daytime ambulatory readings were similar across all five drugs. And in a Nigerian trial, starting with amlodipine and adding hydrochlorothiazide later produced better blood pressure control at 48 weeks than starting with the diuretic and adding amlodipine later, suggesting the sequence of combination matters, not just the drugs chosen.

Does It Matter When You Take It?

Amlodipine’s long half-life means it is less timing-sensitive than many blood pressure drugs, but “less sensitive” does not mean timing is irrelevant. Studies comparing morning and evening dosing show that both schedules reduce daytime blood pressure effectively. The differences show up at night. In one trial, the natural nocturnal blood pressure dip was better preserved with morning dosing, while evening dosing flattened that dip somewhat.

However, the picture has gotten more complicated. A large randomized trial published in 2025 found that bedtime dosing of blood pressure medications (including amlodipine-based regimens) produced a greater reduction in nighttime systolic blood pressure by about 3 mmHg compared with morning dosing, along with better nocturnal blood pressure control, and did not increase the risk of low blood pressure during sleep. Since elevated nighttime blood pressure is itself tied to cardiovascular risk, these few extra points could matter. Still, the earlier study found that both morning and evening amlodipine significantly reduced elevated systolic and diastolic blood pressures during the daytime, and the overall circadian profile was not dramatically altered by either schedule. If your doctor has not specified a time, consistency matters more than the hour on the clock.

How Amlodipine Performs Overnight and in Different Dipping Patterns

Not everyone’s blood pressure follows the standard pattern of dropping at night and rising in the morning. Researchers classify patients as “dippers” (normal nighttime fall), “non-dippers” (minimal fall), or “extreme dippers” (exaggerated fall). Amlodipine’s effect on nighttime blood pressure depends on which category you fall into. In a study of elderly patients with hypertension, amlodipine reduced nighttime blood pressure in non-dippers and, to a lesser extent, in dippers. In extreme dippers, it did not push nighttime readings down any further, which is reassuring since excessive nighttime drops can reduce blood flow to the brain.

The same study found that no blood pressure reduction greater than 10 mmHg occurred when baseline readings were already below 120/70, which suggests amlodipine does not keep driving blood pressure down to dangerous levels once you are already in a normal range. The reduction was proportional to how elevated the starting pressure was.

Combination Therapy and Bigger Drops

When amlodipine alone does not get you to your target, it is commonly paired with an ARB such as valsartan, an ACE inhibitor, or a thiazide diuretic. These combinations work because the drugs target different mechanisms. A review of the amlodipine-valsartan combination found it lowered blood pressure significantly more than either drug alone.

Triple therapy can be even more dramatic. In a trial of patients with diabetes, chronic kidney disease, or existing cardiovascular disease, the combination of olmesartan, amlodipine, and hydrochlorothiazide reduced systolic blood pressure by roughly 38 to 44 mmHg depending on the subgroup, outperforming every two-drug pairing tested. These are large reductions partly because the patients started with high baseline pressures and had conditions that make blood pressure harder to control. For people with milder hypertension who respond to monotherapy, the drop will be far more modest.

Ankle Swelling and Other Side Effects

The most recognizable side effect of amlodipine is ankle and foot swelling. It is not caused by fluid retention in the way heart failure swelling is. Instead, amlodipine dilates the small arteries in your legs without equally dilating the veins, which raises capillary pressure and pushes fluid into the surrounding tissue. The effect is dose-related: higher doses and longer treatment both increase the likelihood. In a study at a hospital in Nepal, about 16% of amlodipine users had some degree of pedal edema, and long-term use beyond five years raised the odds substantially.

There is a practical workaround. Adding an ACE inhibitor or ARB to amlodipine not only improves blood pressure control but also cuts the incidence of swelling. A meta-analysis found that pairing a calcium channel blocker with a renin-angiotensin system blocker reduced peripheral edema by about 38% compared with using the calcium channel blocker alone, and the risk of patients discontinuing treatment because of swelling dropped by roughly 62%. An earlier mechanistic study showed that enalapril (an ACE inhibitor) reduced the amount of fluid that amlodipine pushed into leg tissue, even though it did not fully reverse the underlying vascular changes. This is one reason doctors frequently prescribe the combination pill rather than amlodipine by itself.

Amlodipine in Older Adults and Isolated Systolic Hypertension

Isolated systolic hypertension, where the top number is high but the bottom number remains normal, is the dominant form of high blood pressure in people over 60. Amlodipine works well in this group. In a trial of elderly patients with isolated systolic hypertension, amlodipine 5 to 10 mg reduced systolic pressure by about 27 mmHg with only a small dip in diastolic pressure, comparable to enalapril. Another trial comparing amlodipine to valsartan in elderly patients with isolated systolic hypertension found similar efficacy between the two drugs.

When measured by 24-hour ambulatory monitoring, amlodipine provided more sustained systolic blood pressure reduction than nicardipine, a shorter-acting calcium channel blocker, in elderly patients with isolated systolic hypertension. The difference was especially clear during nighttime hours. For older adults who tend to have their blood pressure measured only during daytime office visits, this kind of sustained round-the-clock action is relevant: the drug does not simply look good on a single clinic reading while fading out at other hours.

Response in Black Patients

Calcium channel blockers, amlodipine included, tend to be particularly effective in Black patients. A comparison of three dihydropyridine calcium channel blockers in African American patients with hypertension found that amlodipine lowered average 24-hour ambulatory blood pressure by about 14/9 mmHg. In a separate trial that compared amlodipine to a different calcium channel blocker formulation specifically in African Americans, amlodipine produced a greater overall 24-hour systolic blood pressure reduction. This is partly why major hypertension guidelines often recommend calcium channel blockers or thiazide diuretics as preferred initial therapy in this population.

Blood Pressure Variability, Not Just the Average

Lowering average blood pressure is the main goal, but how stable that pressure remains from visit to visit also matters. Wide swings in systolic blood pressure between appointments have been linked to increased stroke risk independent of the average reading. Amlodipine turns out to be especially good at smoothing out this variability. A meta-analysis covering more than 47,000 patients found that amlodipine produced significantly less visit-to-visit blood pressure variability than atenolol, lisinopril, and enalapril. A smaller trial comparing amlodipine to losartan showed similar average reductions but found that amlodipine did a better job of keeping home evening readings and day-to-day measurements consistent. This may partly explain why amlodipine-based regimens have performed well in large outcomes trials focused on stroke prevention.

Long-Term Cardiovascular Outcomes

Blood pressure numbers matter because they predict heart attacks, strokes, and death. A meta-analysis comparing amlodipine-based treatment regimens to other antihypertensive strategies found that amlodipine was associated with a roughly 16% reduction in stroke risk and a 9% reduction in heart attack risk compared with non-calcium-channel-blocker regimens. Overall cardiovascular events dropped by about 10%, and total mortality fell by about 5%. The one area where amlodipine looked slightly less favorable was heart failure, where the risk was marginally higher, though this was not statistically significant and disappeared when the comparison was restricted to beta-blockers and diuretics. These outcome advantages likely reflect both the blood pressure lowering itself and amlodipine’s additional properties, including its smooth 24-hour coverage and its ability to reduce blood pressure variability.

Why Some People Get a Bigger Drop Than Others

Not everyone responds to amlodipine equally, and genetics plays a role. The calcium channels that amlodipine blocks are encoded by genes like CACNA1C and CACNA1D, and variations in those genes influence how much your blood pressure falls. A pharmacogenomic study found that patients carrying certain genotypes at these gene locations experienced significantly greater blood pressure reductions than those with other variants. Separate research has pointed to the liver enzymes that metabolize amlodipine, particularly CYP3A5, as another source of variable response: people who carry gene variants that speed up the drug’s breakdown may clear it faster and get less blood pressure lowering from the same dose.

In practical terms, this means that if you are on 5 mg of amlodipine and your blood pressure has barely budged, it does not necessarily mean the drug is wrong for you. Increasing to 10 mg may overcome a faster metabolism or a less-sensitive calcium channel variant. But if 10 mg with adequate time still falls short, your doctor will typically add a second drug from a different class rather than push beyond the maximum dose.

The Grapefruit Question

Many calcium channel blockers carry warnings about grapefruit juice, which can inhibit the enzymes that break these drugs down and cause blood levels to spike. Amlodipine is a mild exception. A study of healthy volunteers found that grapefruit juice increased amlodipine’s peak blood concentration and total exposure by only about 15 to 16%, and this did not translate into a measurable change in blood pressure or heart rate. The interaction exists pharmacologically but appears clinically negligible. You are unlikely to need to avoid grapefruit while taking amlodipine, though it is still worth mentioning to your pharmacist if you drink it regularly, because drug interactions can be unpredictable when multiple medications are involved.

Kidney Considerations

Amlodipine lowers blood pressure in people with kidney disease just as it does in those with healthy kidneys, but its effects on the kidneys themselves are more nuanced. In a head-to-head trial with losartan in patients with proteinuric chronic kidney disease, both drugs controlled blood pressure equally well; however, losartan reduced protein in the urine over 12 months while amlodipine did not change proteinuria at all. Since proteinuria is a marker of ongoing kidney damage, this is why doctors often pair amlodipine with an ACE inhibitor or ARB when kidney disease is present: the combination gets both the blood pressure benefit and the kidney-protective effect.

When amlodipine was combined with atorvastatin (a statin) in patients with chronic kidney disease, the combination lowered blood pressure and also reduced albuminuria without worsening kidney function over 16 weeks. The statin likely contributed independently to the kidney benefit, but the broader point is that amlodipine-based combinations in kidney disease patients can produce systolic blood pressure drops well into the 30s and 40s of mmHg, especially when baseline pressures are very high.

Central Blood Pressure, Not Just Arm Readings

The blood pressure measured at your arm is not identical to the pressure your heart and brain actually experience. Central blood pressure, the pressure in the aorta, is influenced by how stiff your arteries are and how pressure waves bounce back from peripheral vessels. Amlodipine lowers central systolic blood pressure as well. In a study comparing amlodipine to candesartan, central systolic pressure dropped by about 23 mmHg after eight weeks of amlodipine treatment, with no significant difference between the two drugs. Central blood pressure is increasingly recognized as a better predictor of organ damage than arm readings, so knowing that amlodipine addresses both provides some additional reassurance about the drug’s protective effects.